Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses

Cell death pathologies: targeting death pathways and the immune system for cancer therapy

Targeting immunogenic cell stress and death for cancer therapy

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Ferroptosis, Necroptosis, and Pyroptosis in Anticancer Immunity

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope

Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy.

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Nanomaterials: leading immunogenic cell death-based cancer therapies

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death

Programmed Cell Death Tunes Tumor Immunity

Apoptosis, a Metabolic "Head-to-Head" between Tumor and T Cells: Implications for Immunotherapy

Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy

Programmed cell death in tumor immunity: mechanistic insights and clinical implications

How to improve the immunogenicity of chemotherapy and radiotherapy